At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Nivolumab 240 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Hodgkin Lymphoma. Completed, enrolled 37 participants across 6 sites.
Detailed Summary
This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMay 2018
Primary CompletionMay 2022
Study CompletionApr 2023
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartMay 23, 2018
Primary CompletionMay 5, 2022
Study CompletionApr 4, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.4 years ago
Interventions
Nivolumabdrug
Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.